Healthcare News
GLP-1RAs offer comparable weight loss to bariatric surgery with fewer side effects
Tirzepatide 15 mg produced similar weight loss results as bariatric surgery among patients with obesity but had a favorable safety profile, according to a presenter at the ACG Annual Scientific Meeting.
Metabolic and bariatric surgery safe and effective for patients with severe obesity
A team of researchers led by Pennington Biomedical Research Center's Dr. Florina Corpodean has confirmed through a data analysis that metabolic and bariatric surgery is largely safe and effective for patients who are experiencing severe obesity.
Is eating once a day a good idea? Experts share varying opinions on the ‘OMAD diet’
Dubbed the One Meal a Day (OMAD) diet, it’s a form of intermittent fasting that involves eating all the day’s calories in a single meal, after 23 hours of fasting.
Zepbound bests Wegovy for weight loss in new trial
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.
Early weight loss with tirzepatide predictive of larger cardiometabolic benefits later on
Tirzepatide confers significant weight loss and cardiometabolic benefits for patients with diabetes and overweight or obesity, especially for those who lose more weight earlier during treatment
